Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia
about
Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal TransitionNext-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignanciesEpigenetics: A primer for clinicians.A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation.Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.
P2860
Q27307611-D469469B-590E-4379-AE2E-AD1E68DAEB21Q27712238-00F89364-7E06-41A6-BCEE-70094AFBD365Q38770916-E1E7534E-9B92-4929-B8DD-DADBB2F7A9B7Q38881093-BAB46157-BB65-4210-BF7D-3A11DC8DE529Q39135290-D6EF0377-7E38-4C03-9E04-342B059FD2F7Q39175665-1F48766E-BF98-412B-8835-EA8728A84DEAQ39643726-D33E7B51-B9EE-4FF3-9A6F-FD26C91A8A4DQ40963604-65E3FF8A-9AD9-4159-9644-7270E42B55E0Q41087485-43758ABD-10F1-4803-9EE1-1645F5A91A89Q41412563-ADCAA662-6556-4B5A-A250-56067062CCBCQ46887116-DA077F8C-9876-462B-B306-985FD2E078AAQ51157837-41C95EDB-041F-4CA8-817B-A47A7CD6FBA6
P2860
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Decitabine priming enhances th ...... exor in acute myeloid leukemia
@ast
Decitabine priming enhances th ...... exor in acute myeloid leukemia
@en
type
label
Decitabine priming enhances th ...... exor in acute myeloid leukemia
@ast
Decitabine priming enhances th ...... exor in acute myeloid leukemia
@en
prefLabel
Decitabine priming enhances th ...... exor in acute myeloid leukemia
@ast
Decitabine priming enhances th ...... exor in acute myeloid leukemia
@en
P2093
P2860
P1433
P1476
Decitabine priming enhances th ...... exor in acute myeloid leukemia
@en
P2093
Alison Walker
Bhavana Bhatnagar
Jessica Hofstetter
Katherine Walsh
Michael Kauffman
Mitch A Phelps
Parvathi Ranganathan
Ramasamy Santhanam
Ramiro Garzon
Rebecca Klisovic
P2860
P304
P356
10.1182/BLOOD-2014-10-607648
P407
P577
2015-02-25T00:00:00Z